Jumpcan Pharmaceutical is a national high-tech enterprise group, the National Torch Program pharmaceutical industry backbone enterprise, one of top 100 of the national pharmaceutical industry, and the Shanghai Stock Exchange A-share listed company (stock code: 600566), and focusing on the R & D, manufacturing and trading of Chinese Traditional Medicine, Western Medicine, daily use chemical-based on Chinese Traditional Medicine, and Chinese medicine health products. The company has two subsidiaries, Jumpcan Pharmaceutical Group Co., Ltd. and Shanghai Jijia Investment Co., Ltd. Jumpcan Pharmaceutical Group Co., Ltd. has several subsidiaries including Tianji Pharmaceutical, Jiyuan Medicine, Jiren Medicinal Slices, Pudilan Daily Use Chemicals, Kangxuyuan Health Products, Ginkgo Industry Research Institute, Oral Health Research Institute, and Haiyuan Property; Shanghai Jijia Investment Co., Ltd. has few subsidiaries including Ningbo Jijia Investment and Dongke Pharmacy.

The company has more than 10 formulations, over 210 strengths and specifications of No. National Drug of Character Zhun, where more than 110 advantages and specifications are included in the National Directory of Insured Drugs, 68 strengths and specifications are included in the National Directory of Basic Drugs.

The company obtained 38 national invention patents, with more than 10 varieties listed as the Exclusive Domestic Varieties, Exclusive Formulations, High-tech Products in Jiangsu Province. It’s brand including Pudilan, Methylene Blue, and Chuanxiong, “Shoupai” and “Tongxiao”. It’s Pudilan Anti-inflammatory Oral Liquid obtained “The Fourteenth Excellent National Patent Award” and “Excellent Quality Award”.  The new generation of proton pump inhibitor Rabeprazole Sodium Enteric Capsules (Jinuo) won the title of “2015 Excellent Brand of Digestive System in Chinese Chemical Pharmaceutical Industry”.  one pharmaceutical composition for curing exogenous fever and its preparation method (Tongbei) also won the 17th Excellent Chinese Patent Award. The daily use chemical-based on Chinese Traditional Medicine led by “PudilanKeyanning Toothpaste” and Chinese medicine health products led by “Wuxiancao” will keep enhancing the company’s core market competitiveness and promoting the rapid development of big health undertaking.

Established in 1995, Guizhou Sanli Pharmaceutical Co., Ltd. is a modern Chinese patent medicine pharmaceutical enterprise integrating R&D, production, and sales. The company’s product line mainly focuses on pediatrics, respiratory system, cardio-cerebrovascular, gastroenterology, and other fields.

The main products are Kaihoujian spray (child type), Kaihoujian spray, and Qiangli Tianma Eucommia capsules. Among them, the core products Kaihoujian spray (children’s type) and Kaihoujian spray are all national patent products and exclusive varieties in the market. The patent medicine spray market in the throat disease occupies a higher market share and has been used in throat diseases, children A certain brand awareness has been formed in the field of Chinese patent medicine. According to the statistics of the Southern Institute, Kaihoujian spray (including children’s type) ranks first in the throat disease patent medicine spray market, ranking first for three consecutive years, and the throat disease patent medicine spray hospital terminal market has been consecutively Ranked No. 1 in the annual market.

Shanghai Shuangshen Medical Instrument Co,. Ltd. was founded in 2005, headquartered in Shanghai, Qingpu District, Zhangjiang Technology and Industry Park. With its 1.4ha. corporate premises and 120,000 s.f. factories and office building, Shuangshen is a state-chartered medical products manufacturer in the People’s Republic of China.
We produce high-quality CRANIAL MAXILLOFACIAL INTERNAL FIXATION SYSTEMS. Our products are tested and certified by the state institution, have already found application in 500 Chinese hospitals, and have won considerable confidence from physicians and the satisfaction of patients.
Our team consists of 50 qualified and dedicated staff. We apply the highest standards to the quality assurance of our products and the reliability of our services. Our products are researched and developed in collaboration with leading clinics, research institutes, and universities.
In 2014 the company was transformed into a stock corporation, and its shares are traded on the Shanghai Stock Exchange. With an optimistic look to the future, we attach great importance to the continuous development of our products. Our researchers and developers are working on new solutions for neurosurgery, thoracic surgery, and dental implant systems to improve and expand our competencies. Our goal is: in the near future to expand Shuangshen with the help of innovative technology to a leading Chinese market entrepreneur at world quality level.

Yabao Pharmaceutical Group Co., Ltd. is the first listed pharmaceutical company in Shanxi Province and one of the first batch of recognized high-tech enterprises. Integrating R&D, production, logistics, distribution, and planting of traditional Chinese medicines, Yabao has 21 branches and subsidiaries, and over 5600 employees in total. 

Among over 5030 domestic pharmaceutical enterprises, Yabao is ranks 87th.  The Ministry of Industry accredits it as China’s top 100  pharmaceutical enterprises.  Its innovation power is in the top 20, regarded as China’ s best industrial enterprise for the pharmaceutical R&D product line. The trademark of “Yabao” has become a renowned China brand.  

Yabao has 9 production bases in Beijing, Shanghai, Taiyuan, Chengdu, Guiyang, Yuncheng, America and etc, 4R&D bases, 2 traditional Chinese medicine planting bases. All the 9 production bases have passed the new GMP certification, with Beijing Yabao Biopharma having passed the cGMP certification and the No. 3 Branch passed EU GMP certification.

The main products include Chinese and western medicines, APIs and pharmaceutical packaging materials, and the like of over 300 varieties in total. The products for chronic diseases in the elderly and for women and children take a very high share. The patent product, Diarrago, is a national famous-brand. It was awarded the first-class prize of science and technology by the China Association of Chinese Medicine in 2006. and ranked first in Chinese over-the-counter products in 2015. It is the first brand of drugs for children’s external use in China, with a market share of more than 90%.

The company has a globalized professional R&D team, which is composed of 460 R&D staff in total, including 22 Dr. and 150 Masters. Yabao has taken steps to international practice in new drug application, production, and distribution, following the international strategy of  ” research in China and declaration in China, USA, and Europe; production in China and distribution in China, USA, and Europe”.

With more than 3000 salesmen, Yabao has established professional marketing and sales teams  for business channels, OTC retail, terminal at the grass-roots level, hospital investment, OTC investment, APIs, sales development, Beijing biological Pharma, health care consumer products and etc. The company has a perfect sales network, which covers the first, secondary and third markets and terminal markets in 661 counties of 32 provinces and cities.